Literature DB >> 17164998

Antifibrotic effects of hepatocyte growth factor on scleroderma fibroblasts and analysis of its mechanism.

Ryoko Sherriff-Tadano1, Akihide Ohta, Fumitaka Morito, Mio Mitamura, Yoshio Haruta, Shuichi Koarada, Yoshifumi Tada, Kohei Nagasawa, Iwata Ozaki.   

Abstract

We investigated the effect of hepatocyte growth factor (HGF) on collagen metabolism in cultured fibroblasts from scleroderma (SSc) patients and discussed the possible mechanism of its effect. Synthesis of matrix metalloproteinase-1 (MMP-1) and collagen and mRNA levels of various cytokines were examined by enzyme-linked immunosorbent assay and real-time polymerase chain reaction, respectively. Hepatocyte growth factor enhanced MMP-1 production and mRNA levels of MMP-1 and Ets-1 (a transcriptional factor of MMPs). In addition, HGF suppressed collagen synthesis and mRNA levels of procollagenalpha1(I) and connective tissue growth factor (CTGF) in SSc fibroblasts. Expression of transforming growth factor (TGF)-beta1 was not inhibited significantly in SSc or control fibroblasts. Hepatocyte growth factor also increased interferon (IFN)-gamma mRNA significantly in SSc and control fibroblasts. Addition of anti-HGF antibody neutralized these effects of HGF on MMP-1 and collagen synthesis. The results suggest that HGF can suppress collagen accumulation in SSc fibroblasts by increasing MMP-1 levels possibly via activation of Ets-1 and also by decreasing collagen synthesis, which may be partly related to inhibition of CTGF, and increasing IFN-gamma levels rather than the effect on TGF-beta1. The present study indicates that HGF may be a promising therapeutic agent for this intractable disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17164998     DOI: 10.1007/s10165-006-0525-z

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  9 in total

1.  The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.

Authors:  Kristy A Bauman; Scott H Wettlaufer; Katsuhide Okunishi; Kevin M Vannella; Joshua S Stoolman; Steven K Huang; Anthony J Courey; Eric S White; Cory M Hogaboam; Richard H Simon; Galen B Toews; Thomas H Sisson; Bethany B Moore; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

Review 2.  New molecular medicine-based scar management strategies.

Authors:  Anna I Arno; Gerd G Gauglitz; Juan P Barret; Marc G Jeschke
Journal:  Burns       Date:  2014-01-15       Impact factor: 2.744

3.  Hepatocyte growth factor administration increases bone soluble phosphate and alters bone chemical structure in diabetic hypertensive rats.

Authors:  Kamal Awad; Natasha G Boyes; Ramlah Iqbal; Mohamed Ahmed; Adel Mohamed; Pranesh Aswath; Corey R Tomczak; Venu Varanasi
Journal:  J Mater Res       Date:  2021-07-23       Impact factor: 2.909

4.  Blockade of Ets-1 attenuates epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells.

Authors:  Velidi H Rao; Vikrant Rai; Samantha Stoupa; Devendra K Agrawal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-08-07       Impact factor: 4.733

5.  Collagen synthesis is suppressed in dermal fibroblasts by the human antimicrobial peptide LL-37.

Authors:  Hyun Jeong Park; Dae Ho Cho; Hee Jung Kim; Jun Young Lee; Baik Kee Cho; Sa Ik Bang; Sang Yong Song; Kenshi Yamasaki; Anna Di Nardo; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2008-10-16       Impact factor: 8.551

Review 6.  Fibroblast Growth Factor 2 as an Antifibrotic: Antagonism of Myofibroblast Differentiation and Suppression of Pro-Fibrotic Gene Expression.

Authors:  David M Dolivo; Sara A Larson; Tanja Dominko
Journal:  Cytokine Growth Factor Rev       Date:  2017-09-23       Impact factor: 7.638

7.  Anti-fibrotic effect of adipose-derived stem cells on fibrotic scars.

Authors:  Sophie Vanderstichele; Jan Jeroen Vranckx
Journal:  World J Stem Cells       Date:  2022-02-26       Impact factor: 5.326

8.  Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9.

Authors:  Joanna Nikitorowicz-Buniak; Xu Shiwen; Christopher P Denton; David Abraham; Richard Stratton
Journal:  J Invest Dermatol       Date:  2014-06-16       Impact factor: 8.551

9.  Upregulation of miR-23b enhances the autologous therapeutic potential for degenerative arthritis by targeting PRKACB in synovial fluid-derived mesenchymal stem cells from patients.

Authors:  Onju Ham; Chang Youn Lee; Byeong-Wook Song; Se-Yeon Lee; Ran Kim; Jun-Hee Park; Jiyun Lee; Hyang-Hee Seo; Chae Yoon Lee; Yong-An Chung; Lee-So Maeng; Min Young Lee; Jongmin Kim; Jihwan Hwang; Dong Kyun Woo; Woochul Chang
Journal:  Mol Cells       Date:  2014-06-11       Impact factor: 5.034

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.